Anti-diabetic drug utilization of pregnant diabetic women in us managed care by unknown
Knox et al. BMC Pregnancy and Childbirth 2014, 14:28
http://www.biomedcentral.com/1471-2393/14/28RESEARCH ARTICLE Open AccessAnti-diabetic drug utilization of pregnant diabetic
women in us managed care
Caitlin A Knox1*, Joseph AC Delaney2 and Almut G Winterstein1,3Abstract
Background: With the increasing prevalence of type 2 diabetes in young adulthood, treatment of diabetes in
pregnancy faces new challenges. Anti-diabetic drug utilization patterns of pregnant women with pre-existing
diabetes are poorly described. We aim to describe anti-diabetic (AD) agent utilization among diabetic pregnant
women.
Methods: We utilized IMS LifeLink, including administrative claims data of patients in US managed care plans, to
establish a retrospective cohort of women, age 18–46 years (N = 96,740) with billed procedures for a live birth, and
a 12 month eligibility period before and 3 month after delivery. Diabetes mellitus was identified from ≥2 in- or
outpatient claims with diagnoses (ICD-9-CM 250.XX) before pregnancy. We estimated the prevalence of AD drugs
before, during and after pregnancy, and secular trends across the study period (1999–2009), using linear regression.
A sensitivity analysis was conducted to identify the extent of misclassification of trimesters.
Results: Almost six percent (n = 5,581) of the live birth cohort had diabetes mellitus. Throughout the study, 48%
(1999) and 78% (2009) (p < 0.0001) of diabetic women received AD drugs during pregnancy. The most common AD
drugs during pregnancy were insulin, metformin, sulfonylureas, thiazolidinediones (TZD), and combination AD. The
annual prevalence of insulin use increased by only 1% from 39% (1999) to 40% (2009) (p = 0.589) during pregnancy,
while use of sulfonylureas and metformin increased from 2.5% and 4.2% (1999) to 17.3% and 15.3% (2009)
(p < 0.0001), respectively. Insulin and sulfonylurea use steadily increased in prevalence from the 1st to 3rd trimester
(16.5% and 3.3% to 33.0% and 7.5%), while metformin and TZD use decreased (11.4% and 1.6% to 3.8% and 0.2%).
Conclusions: AD use during pregnancy demonstrates the need for additional investigation regarding safety and
efficacy of AD drugs on maternal outcomes.
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Current estimates project that by 2025 one in three
adults in the United States (US) will have diabetes mellitus
[1]. In 2010, approximately 11% of US women aged 20
years or older were either diagnosed or had undiagnosed
diabetes [1]. This reflects an increase in diabetes preva-
lence of 2% in this age group over the last five years, with
a corresponding 1.9 million new cases of diabetes diag-
nosed in 2010 [1]. This growth is almost exclusively attrib-
utable to type 2 diabetes mellitus, which traditionally has
had its onset in later stages of adulthood [1,2].* Correspondence: cknox@ufl.edu
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reproduction in any medium, provided the orThe growing prevalence of type 2 diabetes in young
adults is particularly important, as more young women
will be diagnosed during reproductive years [2]. Poorly
controlled diabetes both before and during the first
trimester of pregnancy can cause major birth defects,
spontaneous abortions, and stillbirths [2]. Despite this
well-established fact, more than 60% of women with
pre-existing diabetes have difficulty managing their
glycemic control during pregnancy [3-5]. Researchers
and providers agree that glycemic control is one of the
most important modifiable risk factors in minimizing
birth defects of infants born to women with pre-existing
diabetes [6-10]. However, little experience and evidence
regarding the safety and effectiveness of oral agents during
pregnancy exists.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thus leaves little choice during pregnancy, type 2 diabetes
may be managed with life-style modifications, oral anti-
diabetic agents, and/or insulin. Among oral agents, several
new molecular entities have been added within the last ten
years with limited data on pregnancy outcomes. Given the
limited research that is available on anti-diabetic agent use
during pregnancy, we aimed to describe anti-diabetic
agent utilization before, during and after pregnancy and
determine secular trends among classes of anti-diabetic
drugs across the 10-year study period (1999–2009) in
women with pre-existing diabetes.
Methods
We utilized the IMS LifeLink Database, which consists
of commercial health plan information from more than
100 managed care plans throughout the US. The majority
of the payer type within the database is commercially in-
sured. The IMS LifeLink database also includes Medicaid,Table 1 Delivery-related procedure (CPT-4) codes used to ide
Code Description
01960 Anesthesia for vaginal delivery only
01961 Anesthesia for cesarean delivery only
01962 Anesthesia for urgent hysterectomy foll
01963 Anesthesia for cesarean hysterectomy w
01967 Neuraxial labor analgesia/anesthesia, pla
01968 Anesthesia for cesarean delivery followi
01969 Anesthesia for cesarean hysterectomy fo
59050 Fetal monitoring in labor, physician w/w
59051 Fetal monitoring in labor, physician w/w
59400 Routine obstetric care, antepartum care
59409 Vaginal delivery only (w/wo episiotomy
59410 Vaginal delivery only (w/wo episiotomy
59412 External cephalic version, w/wo tocolys
59414 Delivery, placenta (separate procedure)
59430 Postpartum care only (separate procedu
59510 Routine obstetric care w/antepartum ca
59514 Cesarean delivery only
59515 Cesarean delivery only; w/postpartum c
59525 Subtotal/total hysterectomy after cesare
59610 Routine obstetric care, vaginal delivery,
59612 Vaginal delivery only, previous cesarean
59614 Vaginal delivery only, previous cesarean
59618 Routine obstetric care, ante/postpartum
59620 Cesarean delivery, after failed vaginal de
59622 Cesarean delivery, after failed vaginal de
99436 Attendance at delivery, at request of de
99440 Newborn resuscitationMedicare, self-insured and unknown payer types. The
database records are generally representative of the com-
mercially insured population in terms of gender and age.
The IMS LifeLink database is comprised of eligibility
and demographic information, as well as, inpatient and
outpatient claims data with detail on diagnosis and pro-
cedures, and prescription drug claims. This database
contained a random sample of 6 million women aged 18
to 46 years with no prescription drug claim for contra-
ceptives. To be included in our study cohort we re-
quired women to have a billed medical procedures code
for live birth (Table 1), and 12 months continuous in-
surance coverage before and 3 months after delivery.
Women were required to have at least one prescription
drug claim before pregnancy, to confirm prescription drug
coverage. A total of 96,740 women met the inclusion
criteria for the cohort.
To identify patients with pre-existing diabetes, we re-
quired two in- or outpatient claims with diagnosis ofntify live births
owing delivery
/o any labor analgesia/anesthesia care
nned vaginal delivery
ng neuraxial labor analgesia/anesthesia
llowing neuraxial labor analgesia/anesthesia
ritten report
ritten report; interpretation only
, vaginal delivery, & postpartum care
&/or forceps)
&/or forceps); w/postpartum care
is
re)
re, cesarean delivery, & postpartum care
are
an delivery
w/antepartum, postpartum care, previous c-section
delivery
delivery; w/postpartum care
, cesarean delivery after failed vaginal delivery, previous cesarean delivery
livery, previous cesarean delivery
livery, previous cesarean delivery; w/postpartum care
livering physician, & stabilization of newborn
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Ninth Revision, Clinical Modification (ICD-9-CM) 250.
XX) within the 3 months preceding conception [11,12].
ICD-9-CM codes identify the specific type of diabetes mel-
litus by the fifth digit of the code, but previous research
suggests that current coding practices do not provide
sufficient accuracy to identify the type of diabetes from
the fifth digit of the ICD-9-CM code [13,14]. Therefore,
we did not separate women according to their diabetes
mellitus type, but decided to present a subgroup ana-
lysis in women with high propensity to have type 2 dia-
betes [15]. For the analysis, we assumed the presence of
type 2 diabetes when 100% of diabetes mellitus diagno-
ses in the claims indicated type 2 diabetes (ICD-9-CM
250. × 0 or 250. × 2) [15]. The “other diabetes” subgroup
included all women with type 1 diabetes mellitus claims
and those with mixed or unspecific claims (i.e., missing
the 5th digit).
We defined the delivery date as the date of the first
Current Procedural Terminology (CPT-4) claim for live
birth for each woman. We included women with live
births only because we needed to obtain an estimated con-
ception date for each woman. Inclusion of terminated
pregnancies would not have allowed the determination of
trimesters because the date of termination relative to con-
ception would be unknown. Since we did not have access
to the Last Menstrual Period (LMP) date, it was necessary
for us to calculate the conception date of the pregnancy.
This was done by subtracting nine months (270 days) from
the delivery date [16,17]. Each trimester of pregnancy was
assigned a 91-day interval [16,17]. Pre-pregnancy interval
were identified as the three months preceding the imputed
conception date to classify the presence of pre-existing
diabetes and capture pre-pregnancy drug utilization. We
separately defined an after pregnancy interval as the three-
month time period after the delivery date, resulting in five
distinct 3-month periods, which were used to define drug
use prevalence.
Because we relied on an imputed conception date, there
was a potential for misclassification of the pre-pregnancy
period and the following trimesters. The risk of misclassi-
fication of the pregnancy periods was particularly high in
women with diabetes, because they are at higher risk for
pre-term births (i.e. shorter gestation periods). In order to
evaluate this effect we conducted a sensitivity analysis,
where we utilized the first healthcare encounter with a
pregnancy code (ICD-9-CM: V22, V23, V72.40, V72.42
and CPT-4:81025) to estimate conception date [18]. Using
the first pregnancy claim as the conception date, the mean
length of pregnancy for the cohort was 6.55 months with
at standard deviation of 1.64 months. Five percent of the
diabetes cohort had an ICD-9-CM claim for early delivery
(644.2, 644.20, and 644.21). Therefore, we conducted an-
other sensitivity analysis where we adjusted the gestationlength to 245 days for women with an early delivery claim
[19]. We saw that the drug class utilization in the sensitiv-
ity analysis did not differ significantly with the originally
imputed pregnancy periods we calculated using 270 days
subtracted from the delivery date.
Among the ten anti-diabetic drug classes identified
within the IMS pregnancy cohort, we focused our analysis
on the five most commonly utilized drug classes before,
during and after pregnancy: insulin, biguanides, sulfonyl-
ureas, thiazolidinediones, and oral anti-diabetic combina-
tions. The remaining anti-diabetic drug classes all showed
prevalence rates of less than 1% (alpha-glucosidase in-
hibitors, amylin analogs, dipeptidyl peptidase-4, GLP-1
receptor agonists and meglitinide analogues). All insulin
products were collapsed into one category reflecting
American Hospital Formulary Service (AHFS) drug class
68.20.08. We calculated respective drug class prevalence
as the proportion of diabetic women with a drug claim of
a particular class during each of the designated periods.
We estimated the prevalence along with the 95% confi-
dence intervals of anti-diabetic drug class utilization be-
fore, during (for each trimester) and after pregnancy. We
investigated the secular trend of annual drug utilization
prevalence using linear regression. All analyses were con-
ducted with SAS 9.2, Cary, NC. The University of Florida
Institutional Review and Privacy Boards approved this
study.
Results
Over the course of the ten-year study period (1999–2009),
we identified 5,581 (5.9%) women with pre-existing dia-
betes among all women with a procedure code for live
birth. A total of 4,043 women had only ICD-9-CM codes
consistent with type 2 diabetes mellitus. Diabetic women
were on average slightly older, had more physician visits
and more prescription drug claims before pregnancy
(Table 2). As expected, diabetic women had a higher
prevalence of additional co-morbid conditions than non-
diabetic women had, but had similar frequencies of smok-
ing, alcohol and drug abuse. Diabetic women also had a
higher prevalence of cesarean section delivery compared
to non-diabetic women, with 44.8% versus 27.2% respect-
ively. There was a higher prevalence of diabetics in the
East region of the US, and a lower prevalence in the South
and West. Within the sub-group analysis, type 2 diabetic
women had similar baseline characteristics, but the aver-
age number of AD prescriptions before pregnancy was
lower in the type 2 diabetes only group when compared
to all diabetic women.
The annual mean age for the diabetic pregnancy cohort
had a statistically significant increase from 29.85 years to
32.90 years from 1999 to 2009 (beta = 0.34, p <0.0001).
The prevalence of anti-diabetic treatment (insulin or
oral anti-diabetic drugs) among diabetic women before
Table 2 Baseline characteristics of the study cohorts
Variable Category DM* DM* Not DM*
N = 5,581 N = 5,581 N = 91,159
T2DM* Other DM*
N = 4,043 N = 1,538
Age: Years (SD) 32.3 (5.1) 32.5 (5.1) 32.1 (5.0) 30.1 (5.3)
Eligibility: Months (SD) 56.8 (25.2) 57.4 (25.2) 55.1 (24.9) 51.3 (24.4)
Physician office visits 3 months before Pregnancy (SD) 21.3 (24.5) 20.8 (25.2) 22.5 (22.5) 14.6 (17.8)
Number of Prescription Drug Claims 3 months before Pregnancy (SD) Anti-Diabetic 3.0 (7.5) 1.4 (4.5) 7.2 (11.2) 0.1 (0.9)
Other 14.6 (18.8) 13.9 (18.5) 16.4 (19.4) 9.7 (12.4)
Delivery Route Vaginal 55.2% 58.8% 47.7% 72.8%
Cesarean Section 44.8% 41.2% 52.3% 27.2%
Comorbid Conditions PCOS 12.5% 13.1% 10.9% 5.5%
Hypertension 18.2% 17.0% 21.4% 4.3%
Infertility 14.7% 15.6% 12.2% 10.6%
IVF Claim 0.1% 0.1% 0.1% 0.0%
Obesity 13.9% 13.4% 15.2% 3.8%
Smoking 6.0% 6.0% 5.9% 4.6%
Alcohol 0.8% 0.8% 1.0% 0.9%
Drug Abuse 0.7% 0.7% 0.6% 0.7%
Region East 32.6% 33.6% 26.6% 20.6%
Midwest 43.1% 43.1% 40.6% 43.8%
South 12.1% 11.1% 19.7% 17.9%
West 12.3% 12.2% 13.2% 17.7%
Conception Year (SD) 2005 (2.4) 2005 (2.3) 2005 (2.6) 2005 (2.6)
*DM = pre-existing diabetes mellitus, T2DM = type 2 diabetes mellitus.
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36.1% (CI: 35.94, 36.26) from 1999 to 2009 (beta = 1.3%,
p <0.0001) (Figure 1). During pregnancy, we observed a
statistically significant rise in anti-diabetic drug treat-
ment from 48.3% in 1999 to 77.9% in 2009 (beta = 3.4%,
p < 0.0001). The growth in the prevalence of treatment was
similar across trimesters with the largest growth in theFigure 1 Annual prevalence of anti-diabetic treatment before, duringthird trimester, which saw a 23% increase in treatment from
36.8% (CI: 36.58, 37.01) in 1999 to 59.4% (CI: 59.18, 59.62)
in 2009 (beta = 2.4%, p <0.0001). The prevalence of diabetic
women who were treated with an anti-diabetic drug after
pregnancy approximately doubled from 18.3% (CI: 18.11,
18.49) to 39.7% (CI: 39.51, 39.89) from 1999 to 2009 at a
rate of 1.8% (CI: 1.14, 2.53) per year (p <0.0001) (Figure 1).and after pregnancy.
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sulfonylureas showed the greatest increase over the study
period from 4.2% (CI: 4.11, 4.29) and 2.5% (CI: 2.44, 2.56)
in 1999 to 15.3% (CI: 15.21, 15.39) and 17.3% (CI: 17.26,
17.36) in 2009, respectively (p <0.0001 for each drug class)
(Figure 2). The sulfonylurea drug class included glime-
pride, glipizide, and glyburide at 28%, 47% and 25% re-
spectively. Thiazolidinediones and combination drugs
remained constant at 1.6% (CI: 1.56, 1.64) and 0.5% (CI:
0.47, 0.53) over the course of the study. As expected
rosiglitazone saw a decrease from 50% to 23.1% within
the thiazolidinesdione drug class (beta = −3.4, p = 0.12).
Insulin use during pregnancy increased 1% over the 10-year
period from 39% (CI: 38.81, 39.19) in 1999 to 40% (CI:
39.81, 40.19) in 2009 (p-value = 0.589 (Figure 2).
When pooled across the entire study period, the
prevalence of metformin use before pregnancy in all dia-
betic women was 13.7% (CI: 13.11, 14.28), which de-
creased to 12.3% (CI: 12.21, 12.39) during pregnancy
and then decreased further after pregnancy to 7.7% (CI:
7.62, 7.78) (Figure 3). Insulin utilization behaved as ex-
pected, with a lower average prevalence before preg-
nancy of 10.7% (CI: 10.52, 10.88), which more than
tripled to 35.3% (CI: 35.11, 35.48) during pregnancy and
then dropped again to 11.8% (CI: 11.67, 11.93) after
pregnancy. Sulfonylurea utilization followed a surpris-
ingly similar trend, as the pre-pregnancy baseline preva-
lence of 3.1% (CI: 3.08, 3.12) grew during pregnancy to
10.4% (CI: 10.34, 10.46) and then decreased to 2.5% (CI:
2.43, 2.57) after pregnancy.
In sub-group analysis of the type 2 diabetic women only,
the pattern of anti-diabetic drug utilization was very simi-
lar to all diabetic women, except an expected lower preva-
lence of insulin use throughout each 3-month period. We
noted an even lower rebound in utilization of metformin
after pregnancy, with only 5.6% (CI: 5.51, 5.69) of type 2
diabetic women who used metformin post-delivery, but
more than 12.4% (CI: 12.30, 12.50) before pregnancy.Figure 2 Annual prevalence of anti-diabetic drug utilization during pDiscussion
We conducted a descriptive analysis on anti-diabetic drug
utilization before, during and after pregnancy in diabetic
women in order to guide future research on drug safety
and effectiveness. Our study had several key findings.
First, overall anti-diabetic drug utilization during preg-
nancy doubled over our ten-year study period. Second,
despite this increase, we found a significant proportion
of diabetic women with no drug treatment before, dur-
ing and after pregnancy. Third, among the anti-diabetic
drug classes we found interesting AD utilization pattern
indicating changes in the treatment regimen during
pregnancy. For example, the prevalence of metformin
utilization decreased as pregnancy progressed from the
1st to the 3rd trimester, but was re-established into the
treatment regimen after pregnancy, although at less than
half the prevalence of the before period. Insulin and sulfo-
nylurea demonstrated a reversed pattern, as the overall
prevalence of utilization in both drug classes increased
over the course of pregnancy and then returned to a low
prevalence after pregnancy similar to utilization before.
Current recommendations for the initial therapy of
diabetes (both type 1 and type 2) emphasize pharmaco-
logical interventions [20]. According to the American
Diabetes Association (ADA) and the European Associ-
ation for the Study of Diabetes (EASD), the initial manage-
ment of type 2 diabetes should use combination therapy
of metformin and lifestyle changes with augmentation of
therapy with additional oral anti-diabetic drug to maintain
glycemic control [20]. Or initiate insulin at diagnosis for
individuals who present with severe hyperglycemic symp-
toms [20]. The recommendation reflects a change in treat-
ment approaches a decade ago, which suggested that early
type 2 diabetes might be managed with diet and lifestyle
modifications alone. This evolution in treatment paradigm
may explain the increase in overall anti-diabetic drug
utilization that we observed among diabetic women be-
fore, during, and after pregnancy over our study period.regnancy by drug class.
Figure 3 Pooled annual prevalence of anti-diabetic drug
utilization, by drug class: before, during, and after pregnancy.
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Survey, for the past ten years the prevalence of diabetic
adults who do not use insulin or oral anti-diabetic drugs
to control their diabetes has slightly grown by 1% to more
than 15% of US adults with diabetes [2,21]. The fact that
we observed even higher proportions of non-treated pa-
tients in a managed care population with comprehensive
drug benefits and increased medical attention due to preg-
nancy is surprising and raises questions about current
treatment approaches. While the majority of pregnant
woman may have had onset of type 2 diabetes in recent
years and thus limited need for aggressive glycemic con-
trol, we still expected that current treatment guidelines
and the emphasis on tight glucose control during preg-
nancy would have resulted in more comprehensive drug
therapy. Unfortunately, because laboratory values are not
available in claims data, it is unclear whether these women
were able to achieve or maintain normoglycemia through-
out pregnancy.
In general, the use of insulin to treat type 2 diabetes
mellitus during pregnancy is accepted and recommended
as safe and effective in achieving normal blood glucose
levels [22,23]. There is also sufficient evidence to support
that metformin is non-inferior to insulin with regards to
neonatal safety, but comparative data regarding efficacy
during pregnancy are lacking [24,25]. Furthermore, the
majority of the metformin safety studies have been com-
pleted in women with polycystic ovarian syndrome or
gestational diabetes, not in women with pre-existing
diabetes, and have not evaluated pregnancy outcomes
(pre-term labor, preeclampsia, cesarean section delivery)
as safety endpoints [24,26].
The distinct increase of sulfonylureas use during preg-
nancy observed in this cohort was noteworthy in this
context, because this drug class is currently not recom-
mended for this indication, including an FDA contra-
indication for use in the last 4 weeks of pregnancy. This
notwithstanding, several studies have found no harmfuleffects and report good glycemic control with the
use of sulfonylureas during pregnancy [27-30]. Again,
the majority of studies on the use of this drug class
in pregnancy address the use in gestational diabetic
women and lack evidence on various aspects of safety
and efficacy.
We conducted this study using administrative claims
data. The IMS LifeLink database allowed us to investigate
the prevalence of diabetes in pregnancy in a relatively large
cohort of more than 96,000 pregnant women, sampled
from over 100 commercial health plans across the US,
with fully adjudicated medical and pharmaceutical claims.
The study period, which spanned ten years, allowed for
the examination of time trends in drug utilization of these
women before, during and after pregnancy. Focus on a
managed care setting allowed good observation of pre-
scribing practices, because access to care is not a major
limitation.
All administrative data have limitations and this study
is no exception. Despite our large sample size, focus on
women in private insurance is not representative of dia-
betes treatment pattern in the US. In addition, the selec-
tion of health plans in IMS may not be representative as
suggested by the geographic distribution of diabetes
prevalence that does not follow nationally reported data.
However, comparisons across time and across trimes-
ters are expected to be valid within the study cohort. By
restricting the pregnancy cohort to only women with a
prescription drug claim before pregnancy, we are omit-
ting women without drug coverage and theoretically
omitting women who are not receiving drug treatment
or who are non-adherent to their medication regimen.
We potentially underestimated drug use prevalence in
instances where pharmacy claims were not submitted
for reimbursement because patients paid cash for their
prescriptions. However, since prescription copays should
have provided cheaper alternatives to patients during the
study period, we expect minimal misclassification. We
limited this descriptive analysis to pregnant women with
live births. Therefore, the drug utilization patterns that
were seen within this descriptive analysis may be different
from pre-existing diabetic women with unsuccessful preg-
nancies (i.e. miscarriage, stillbirth, or termination).
Finally, we aimed to focus our study on patients with
type 2 diabetes, but had to accept limitations in the
granularity of ICD9-CM codes used for billing. Studies
have been largely unsuccessful in validating algorithms
to distinguish between diabetes types [13-15,31]. In
order to estimate the extent of potential misclassifica-
tion we provide results of a sensitivity analysis using a
conservative approach that did not allow any codes for
type 1 or unspecified diabetes in our sub-cohort of type
2 diabetic patients. This approach was likely not sensi-
tive and may have excluded patients differentially.
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Pre-existing diabetes is an increasing comorbidity in
pregnant woman in the US. While the overall use of
anti-diabetic medications during pregnancy increased, a
larger than expected proportion of pregnant women did
not have AD drug claims throughout the study period.
Contrary to current recommendations, metformin use
decreased as pregnancy progressed while sulfonylurea
use increased. The high rate of oral anti-diabetic drug
use during pregnancy emphasizes the need for conclusive
evidence regarding safety and efficacy in terms of glucose
control as well as maternal outcomes. Further research is
needed in order to evaluate the safety of oral anti-diabetic
agent use in pregnant women with pre-existing diabetes in
terms of pregnancy and neonatal outcomes. Within this
study, it we were unable to assess the impact of glycemic
control and co-morbid conditions on the choice of anti-
diabetic agents throughout pregnancy. Therefore, it will
also be important for future research to focus on the de-
terminates of medication choices during pregnancy in-
cluding the presence or on-set of co-morbid conditions
and changes in glycemic control. Additionally, the lower
prevalence of anti-diabetic drug utilization post-delivery
indicates a possible need for further investigation.
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